老熟女另类,老熟女乱伦,老熟女乱婬一区二区,老熟女毛茸茸,老熟女毛茸茸黑森森,老熟女毛茸茸浓毛,老熟女网,老熟女网站。

CN / EN

News

Technoderma Medicines Advances TDM-180935 Atopic Dermatitis Clinical Program with Phase 2 Trial

Release time: 2024-04-30 Article source: 特科羅

CHENGDU, China, April 29, 2024 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing patients in its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment. This clinical trial in the Atopic Dermatitis (AD) program includes 8 weeks dosing of two different active formulation strengths and placebo in a study entitled, "A Randomized, Vehicle-Controlled, Parallel Group Study of Topical TDM -180935 to Evaluate the Preliminary Efficacy, Safety, Tolerability, and Pharmacokinetics in Atopic Dermatitis Patients". It is a randomized, vehicle-controlled, parallel group comparison study with an open-label PK sub-study.  Objectives are to evaluate the safety and efficacy of topical TDM-180935 as well aspharmacokinetics. Seven U.S. clinical sites are currently participating in this study under an open IND with FDA.

Arthur P. Bertolino, MD, PhD, MBA, Chief Medical Officer at Technoderma Medicines commented, "We expect the current study to support Proof-of-Concept for TDM-180935 regarding efficacy and to guide choice of formulation strength(s) appropriate for continued development in our AD program. We are encouraged by the selective advantages that maybe provided by TDM-180935 as a potent JAK1/Tyk2 small molecule inhibitor."


About TDM-180935

TDM-180935 is a small molecule drug candidate being developed as a topical drug for treatment of Atopic Dermatitis. As a potent JAK1/Tyk2 small molecule inhibitor, it may offer significant advantages regarding efficacy and safety compared to existing topical treatments. Preclinical assessment of TDM-180935 has demonstrated efficacy in multiple models and that it is well-suited for topical administration. Functional cell assays demonstrate that TDM-180935 can effectively suppress both keratinocyte- and T cell-derived pathogenic pathways characteristic for Atopic Dermatitis. Testing in rats and minipigs demonstrated favorable toxicology and toxicokinetic profiles. Phase 1 clinical testing of topical TDM-180935 ointment has demonstrated excellent toleration and minimal systemic absorption.

About Atopic Dermatitis (AD)


Atopic Dermatitis (AD), also called eczema, is a chronic relapsing pruritic inflammatory skin disorder that typically affectsthe face,neck, hands and feet, and flexor aspects of extremities. Depending on disease stages (acute, subacute, chronic),typical AD lesions include redness, swelling,cracked or excoriated skin, scaly erythema or plaques with or without exudates,and lichenification, accompanied by severe pruritus and skind ryness. Repeated scratching triggers a self-perpetuatingitch-scratch cycle, which can have a significant impact on quality of life. The worldwide prevalence of AD is estimated to be15-20% in children and 1-3% in adults, and the incidence has increased by 2- to 3-fold during the past decades in industrializedcountries. The pathogenesis of AD involves four major aspects: disruption of skin barrier function,exposure to allergens,microbial infection, and dysregulated immune function. There are two  major risk factors of developing AD:one is the geneticdefect in the gene FLG encoding profilaggrin, the precursor of filaggrin protein present in the granular layer of the epidermiswhere it brings structural proteins together to create a strong barrier matrix; the other major risk factor is a family historyof atopic diseases such as food allergy, allergicrhinitis, and asthma.


About Technoderma Medicines


Technoderma Medicines, Inc. is a privately held clinical stage biopharmaceutical company located in Chengdu Tianfu BioPark,Sichuan, China. Its current core programs focus on development of innovative therapies for Androgenetic Alopecia,Atopic Dermatitis, Psoriasis and Lupus Erythematosus. Its "first-in- class" small molecule thyromimetic drug candidateTDM-105795 for Androgenetic Alopecia successfully completed Phase 2a clinical testing and is further advancing in development.Technoderma's novel JAK1/TYK2 inhibitor TDM-180935 for Atopic Dermatitis completed Phase 1 clinical testing with a favorablesafety profile and is now entering Ph2a testing. The pipeline targets dermatologic indications.


INVESTOR AND MEDIA CONTACT


Technoderma Medicines, Inc.

Zengquan Wang, PhD, CEO

[email protected]






主站蜘蛛池模板: 国产免费观看av大片的网站 | 国产噜噜噜精品免费 | 欧美日韩一区二区三区在线 | 一区二区三区精品视频日韩 | 日韩欧美人妻一区二区三区 | 91午夜福利国产在线观看 | 精品黄色一区二区三区 | 欧美v亚洲v综合v国产v | 日韩免费观看 | 99视频免会员观看最新版下载 | 中文字幕人成乱码熟女 | 亚洲精品一区二区 | 日韩超碰人人爽人人做人人添 | 视频一区国产精品自拍 | 黄色一级片免费在线观看 | 蜜臀色欲av无码国产精品 | 国产免费一区二区三区在线观看 | 蜜柚视频在线观看免费完整 | 午夜dj视频免费观看www | 无卡码一区二区久久 | 2025在线观看片免费人成视 | 成人精品免费国产一区二区 | 亚洲精品岛国片在线观看 | 91视频直播app安卓版免费下载安装 | 91精品伊人久久久大香线蕉91 | 老司机网站色奇吧久久 | 亚洲国产欧美在线观看一区 | 97性无码区免费 | 精品无码国产一区二区三区51 | 免费a级毛片无码视频 | 日韩一区二区三区国产高清 | 亚洲熟女少妇一区二区三区 | 国产老湿机福利视频在线观看 | 欧美日韩精品久久久免 | 精品国语任你躁在线播放 | 免费黄网站在线观看 | 亚洲国产精品一区二区三区久久 | 老熟妇乱日本在线视频 | 99re这里是国产| 免费男人下部进女人下部视频 | 91精品久久香蕉国产线看观看 |